Skin Biopsies Diagnosed Mitochondrial Disease
Researchers verified that fibroblast functional testing identifies conditions that genetic screening often misses.
Updated on Oct. 6, 2026 in Life Sciences
Live Poll
Should medical institutions prioritize functional skin biopsies over invasive diagnostic procedures for rare diseases?
A study published in EMBO Molecular Medicine has confirmed that skin biopsies effectively diagnose mitochondrial diseases. The method offers a non-invasive alternative to muscle or liver tissue sampling for patients.
Why it matters
Genetic testing currently provides a definitive cause in only 50% to 65% of cases, often leaving clinicians with inconclusive results. This functional approach aims to resolve those gaps without requiring more invasive procedures.
The study utilized samples across 30 medical centers to assess mitochondrial performance in fibroblasts—skin-derived cells used for laboratory analysis. This test distinguishes affected patients from healthy ones, serving as a functional metric for cases where genetic sequencing fails.
The players
Children's Hospital Colorado
A pediatric healthcare system that served as a primary research site for the study.
University of Colorado Anschutz
A research institution that co-led the study investigating mitochondrial functional testing.
The details
Researchers measured mitochondrial performance by assessing cellular function in fibroblasts. Fibroblasts are skin cells that can be grown in culture to allow for controlled metabolic testing. By evaluating these cells, the team successfully identified mitochondrial disease in patients who had previously received inconclusive results from standard genetic screenings, which often return variants of uncertain significance.
Timeline
October 6, 2026: The research findings were published online.
The Tech Race
This research follows a pattern set by the diagnostic limitations of clinical genetic testing by providing a functional diagnostic workaround. It marks a shift toward standardized physiological testing as a necessary complement to genomic sequencing in complex metabolic care.
This diagnostic method provides a less invasive option for the 1 in 5,000 people estimated to be affected by mitochondrial disease. It offers clinicians a clearer pathway to a diagnosis when standard genetic sequencing fails to identify a definitive cause.
The takeaway
Clinicians can now leverage fibroblast functional testing to improve diagnostic yields for patients with unexplained symptoms. Future adoption of this protocol across specialized medical centers will likely refine the diagnostic standard for rare mitochondrial conditions.
Further reading
For additional context on advancements in diagnostics, visit the Life Sciences section.
More information
Review the complete study published in EMBO Molecular Medicine for detailed methodology.
Source note: This article includes information reported by News-Medical.
Live Poll
Should medical institutions prioritize functional skin biopsies over invasive diagnostic procedures for rare diseases?
